Microbio Co

Microbio Co P/B

The P/B (Price-to-Book Ratio) of Microbio Co (4128.TWO) as of Nov 4, 2026 is 1.20. In the previous year, P/B (Price-to-Book Ratio) was 1.04 — a change of 15.62% (higher).

P/B

1.20

YoY

15.62%

Last updated:

P/B (Price-to-Book Ratio) of Microbio Co is 2025 1.20 . P/B (Price-to-Book Ratio) of Microbio Co was 2024 1.04 . It decreases by 15.62% higher compared to the previous year.

The Microbio Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
1.46 TWD
Jan 1, 2019
1.59 TWD
Jan 1, 2020
1.01 TWD
Jan 1, 2021
0.90 TWD
Jan 1, 2022
0.88 TWD
Jan 1, 2023
0.91 TWD
Jan 1, 2024
1.04 TWD
Jan 1, 2025
1.20 TWD
The Microbio Co P/B history
YEARP/BYoY
1.20+15.62%
1.04+14.61%
0.91+2.39%
0.88-1.65%
0.90-10.64%
1.01-36.87%
1.59+9.26%
1.46+5.37%
1.38-6.37%
1.48+5.72%
1.40+1.56%
1.38—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Microbio Co Stock analysis

What does Microbio Co do? Microbio Co., Ltd. generates revenue through the sale of fermentation products like Tien Chun Bao (TCB) oral solutions, herbal products such as the LeeHerb series, and organic foods including vegetables, fruits, nuts, pastry, seasonings, and organic meals. The company also sells new medicines, including anticancer drugs, hepatitis treatments, allergy medications, and rheumatoid arthritis therapies. Domestic market sales form the primary distribution channel for all product lines. The firm targets consumers seeking natural health solutions through its Tien Chun Bao and LeeHerb product lines, while healthcare professionals and patients requiring specialized treatments purchase its new medicines. Organic food buyers include health-conscious individuals and households looking for sustainable dietary options. All products are sold within Taiwan's domestic market, with no international distribution mentioned. Microbio Co., Ltd. focuses on three core product segments: fermentation-based health solutions, herbal healthcare products, and organic food items. The anticancer and hepatitis medicine segments serve medical professionals and patients in Taiwan, while allergy and rheumatoid arthritis treatments target specific patient groups. The company's product portfolio is fully contained within Taiwan's domestic market, with no indication of international expansion. Microbio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Microbio Co stock

P/B (Price-to-Book Ratio) of Microbio Co is 1.20 in 2025.

P/B (Price-to-Book Ratio) of Microbio Co changed from 1.04 to 1.20, representing a 15.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Microbio Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Microbio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Microbio Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Microbio Co